Cumulative adherence to treatment protocol
| . | Induction (N = 91) . | Consolidation (N = 75) . |
|---|---|---|
| Carfilzomib treatment adherence | ||
| Normal completion | 54 (59) | 52 (69) |
| Dose delay, reduction and/or interruption | 32 (35) | 19 (25) |
| Premature stop | 5 (5) | 4 (5) |
| Thalidomide treatment adherence | ||
| Normal completion | 47 (52) | 56 (75) |
| Dose delay, reduction, and/or interruption | 35 (38) | 9 (12) |
| Premature stop | 9 (10) | 10 (13) |
| Dexamethasone treatment adherence | ||
| Normal completion | 71 (78) | 55 (73) |
| Dose delay, reduction, and/or interruption | 15 (16) | 15 (20) |
| Premature stop | 5 (5) | 5 (7) |
| . | Induction (N = 91) . | Consolidation (N = 75) . |
|---|---|---|
| Carfilzomib treatment adherence | ||
| Normal completion | 54 (59) | 52 (69) |
| Dose delay, reduction and/or interruption | 32 (35) | 19 (25) |
| Premature stop | 5 (5) | 4 (5) |
| Thalidomide treatment adherence | ||
| Normal completion | 47 (52) | 56 (75) |
| Dose delay, reduction, and/or interruption | 35 (38) | 9 (12) |
| Premature stop | 9 (10) | 10 (13) |
| Dexamethasone treatment adherence | ||
| Normal completion | 71 (78) | 55 (73) |
| Dose delay, reduction, and/or interruption | 15 (16) | 15 (20) |
| Premature stop | 5 (5) | 5 (7) |